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Abstract MicroRNAs (miRNAs) are non-protein coding
molecules with important regulatory functions; many have
tissue-specific expression patterns. Their very small size in
principle makes them less prone to degradation processes,
unlike messenger RNAs (mRNAs), which were previously
proposed as molecular tools for forensic body fluid
identification. To identify suitable miRNA markers for
forensic body fluid identification, we first screened total
RNA samples derived from saliva, semen, vaginal secre-
tion, and venous and menstrual blood for the expression of
718 human miRNAs using a microarray platform. All body
fluids could be easily distinguished from each other on the
basis of complete array-based miRNA expression profiles.
Results from quantitative reverse transcription PCR (RT-
PCR; TaqMan) assays for microarray candidate markers
confirmed strong over-expression in the targeting body
fluid of several miRNAs for venous blood and several
others for semen. However, no candidate markers from
array experiments for other body fluids such as saliva,
vaginal secretion, or menstrual blood could be confirmed
by RT-PCR. Time-wise degradation of venous blood and
semen stains for at least 1 year under lab conditions did not
significantly affect the detection sensitivity of the identified
miRNA markers. The detection limit of the TaqMan assays
tested for selected venous blood and semen miRNA
markers required only subpicogram amounts of total RNA
per single RT-PCR test, which is considerably less than
usually needed for reliable mRNA RT-PCR detection. We
therefore propose the application of several stable miRNA
markers for the forensic identification of blood stains and
several others for semen stain identification, using com-
mercially available TaqMan assays. Additional work
remains necessary in search for suitable miRNA markers




MicroRNAs (miRNAs) belong to a class of small non-
protein coding RNA molecules of 18 to 22 nucleotides in
length that negatively regulate gene expression. Associated
with a multiprotein complex, the RNA-induced silencing
complex (RISC) miRNAs hybridize to the 3′UTR of
specific messenger RNA (mRNA) targets, causing inhibi-
tion of mRNA translation and/or mRNA degradation [1]. A
number of miRNAs have been implicated in the processes
of embryonic development, cell proliferation, and differen-
tiation, as well as in the pathogenesis of many human
diseases such as cancer and neurodegenerative and meta-
bolic disorders [1, 2]. Taking into account the involvement
of miRNAs in developmental processes, it is not surprising
that several recent studies revealed tissue-specific expres-
sion patterns of many miRNAs [3, 4]. Correctly identifying
body fluids in forensic practice is important for crime scene
reconstruction, and commonly used protein-based assays
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DOI 10.1007/s00414-009-0402-3are prone to various limitations [5, 6]. Recently, mRNA
profiling has been proposed as a sensitive and specific
method for forensic applications, particularly the use of
mRNAs with tissue-specific expression for body fluid
identification [7, 8]. It has been shown that several mRNA
markers with tissue-specific expression pattern can be
detected in biological stains after long periods of storage
under dry, sun-protected, and ambient-temperature condi-
tions, making them potentially useful for body fluid
identification in forensic practice [9]. However, mRNA
degradation is expected to be greatly promoted by aggressive
environmental factors (e.g., UV light, moisture, and heat); all
can be relevant for forensic samples. Since physical fragmen-
tationofRNAmoleculesduetodegradationdictatestheuseof
very short amplicons for successful PCR detection, the
intrinsically short miRNAs hold promises for being ideal
markers for forensic applications and in case of significant
differential expression, for forensic body fluid identification.
The number of identified miRNAs is constantly growing,
currently reaching many hundreds of species for humans.
Such number requires the use of high-throughput methods,
such as microarrays, for effective miRNA candidate screen-
ing. Here, we applied custom microarrays using LNA™-
modified oligonucleotides as capture probes for 718 known
human miRNAs to samples from five forensically relevant
bodyfluidsofseveral individuals. CandidatemiRNA markers
identifiedfrommicroarraydatawerevalidatedusingTaqMan-
based reverse transcription PCR (RT-PCR) technology and
Northern blotting, thus providing robust confirmation of
differentially expressed miRNA markers with different
methods. MiRNA markers with confirmed differential ex-
pression were further tested for degradation stability, and
additionally, the sensitivity of marker-specific TaqMan assays
was assessed.
Materials and methods
Body fluid samples and RNA extraction
Body fluids, i.e., saliva, venous blood, menstrual blood,
semen, and vaginal secretion, were collected from three male
and three female volunteers with informed consent. For saliva
collection, volunteers were asked toavoid eating and drinking
for at least half an hour before sampling, and each
unstimulated 2 mL saliva specimen was expectorated into a
50-mL Falcon tube placed on ice and immediately processed
for RNA isolation. Venous blood samples were obtained by
vein puncture using dry Vaccutainer tubes; within minutes,
before coagulation occurred, 1 mL of blood was added to
RNA extraction buffer. Menstrual blood and vaginal secretion
samples were obtained using overnight tampons. Semen
samples were collected by ejaculation in 50-mL Falcon tubes,
left for ∼5 min at RT until liquefaction of the ejaculate, and
1-mL aliquots were added to RNA extraction buffer supple-
mented with 50 mM β-mercaptoethanol to ensure complete
lysis ofthe spermcells.Time-wise-degradedseriesofsamples
wereobtainedbystorageofeithercottonswabs(blood,saliva,
and semen) or tampons (menstrual blood and vaginal
secretion) at ambient dust-free lab conditions (no UV
exposure, artificial light exposure, limited day light exposure,
and room temperature and room humidity without significant
variations) for a period of up to 1 year. Total RNA extraction
was performed using the RNA-Bee reagent (Bio-Connect,
Huissen, The Netherlands) following the instructions of the
manufacturer.PotentialtracesofgenomicDNAwereremoved
with DNase I digestion performed with Ambion’s Turbo
DNA-free kit (Applied Biosystems, Nieuwerkerk aan den
IJssel,TheNetherlands)accordingtomanufacturer’spr ot ocol .
The purity and quantity of RNA were assessed with a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA).
Microarray analysis
MiRNA profiling experiments using LNA™-modified oligo-
nucleotides (Exiqon, Vedbæk, Denmark) as capture probes
were essentially performed as described by Pothof et al. [10]
with the exception that the capture probes used here were
based on version 10.1 of the miRNA registry (http://www.
mirbase.org). The arrays were capable of detecting the
expression levels of 718 human miRNAs as well as the full
complement of rodent miRNAs, various additional non-
protein coding RNAs, and some viral miRNAs. The
hybridization signals of 2,688 spots were normalized using
quantile algorithm. Data points with low signal intensities
(<10) in all the samples were excluded from further analysis.
Hierarchical clustering, significance analysis of microarrays
(SAM), and one-way analysis of variance (ANOVA) were
performed using TM4 software [11]. The subsets of miRNAs
that best characterize each body fluid were identified using
nearest shrunken centroids method implemented in prediction
analysis of microarrays (PAM) software [12]. The selection of
differentially expressed miRNA markers for subsequent
confirmation via quantitative RT-PCR analysis was mainly
based on PAM scores, but also invoked the fold-change of
differential expression and absolute expression levels. Prefer-
ence was given to markers that are abundant in the target body
fluids, but are only minimally expressed in the non-target
ones.
TaqMan RT-PCR
Validation of the expression of selected miRNA markers
was performed using commercially available pre-designed
TaqMan RT-PCR assays (Applied Biosystems, Nieuwer-
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supplementary materials, Table 1 for details) using the very
same RNA samples that were used for the microarray
profiling. The TaqMan MicroRNA Reverse Transcription
Kit (Applied Biosystems) was used for the preparation of
cDNA. Reverse transcription reactions were performed in a
volume of 15 μL, and each reaction contained 100 ng of
total RNA and either single or multiple (pentaplex) stem-
loop miRNA-specific primers in experiments of fresh and
time-wise-degraded samples. Two microliters of a 2.5-fold
diluted cDNA mix was used as input in each individual
PCR. For the assay sensitivity test, a 10-fold dilution series
of total RNA was used, ranging from 20 to 0.002 ng per
pentaplex RT reaction. All TaqMan assays were run in
triplicate on an ABI Prism 7300 using TaqMan universal
PCR master mix without UNG (Applied Biosystems) and
applying 45 PCR cycles. Amplification signals were
computed with the SDS v.2.1 software (Applied Biosystems).
Relative quantification of miRNA expression was performed
by the delta Ct (dCt) method using the average expression of
three reference control genes (small RNAs RNU24, RNU44,
and RNU48 analyzed by commercially available TaqMan
assays) for normalization of miRNA abundances across the
tissues. The expression levels for each marker were converted
in a linear scale as fold-change (FC) values calculated by the
formula:FC=2**dCt.Errorpropagationformulawasusedfor
the calculation of standard deviations (SD) of the average
fold-change of expression: SDFC=Ln(2)*SDdCt*FC, where
SDdCt ¼ SQRT SDtargetCt»»2 þ SDreferenceCt»»2

=SQRTðnÞ,
n = number of replicates (normally 3).
Northern blotting
Total RNA was isolated from two semen and two vaginal
secretion samples with TRIzol reagent (Invitrogen, Carls-
bad, CA, USA). Ten micrograms of RNA per sample was
fractionated on a denaturing 15% polyacrylamide gel along
withanUltra Low-Range Gene-Ruler DNAladder(Fermentas
AG, Germany). After the gel run, the size ladder was cut
from the polyacrylamide gel and stained with ethidium
bromide and photographed for future determination of the
size of hybridized fragments. RNA present in the remain-
der of the gel was transferred to a nylon membrane
(Hybond N+; Amersham Pharmacia Biotech, Rosendaal,
The Netherlands) by electroblotting. After being UV-cross-
linked (120 mJ) and baked at 80°C for 30 min, the
membrane was hybridized with an miR-891a LNA probe
(Exiqon A/S, Vedbæk, Denmark) at 65°C overnight in
PerfectHyb Plus hybridization buffer (Sigma-Aldrich, The
Netherlands). Hybridization signals were detected with
chemiluminescent NEB Phototope®-Star Detection Kit
(Westburg BV, Leusden, The Netherlands) according to
the manufacturer’s instructions. Blots were scanned with
Typhoon 9410 system (GE Healthcare, Brussels, Belgium).




After filtering out the low-intensity hybridization signals
across all body fluid and individual samples, 458 of 718
(63.8%) miRNAs remained in the dataset and were used for
further analysis. Unsupervised hierarchical clustering of
normalized hybridization values revealed that samples
belonging to the same body fluid tend to cluster together
(Fig. 1) and that different body fluids display distinct
miRNA expression signatures. Hence, based on the micro-
array results, all five body fluids could be clearly
differentiated from each other based on miRNA expression.
SAM and ANOVA analyses provided largely identical sets
of differentially expressed miRNAs (results not shown). In
search for the most informative miRNA markers, the PAM
algorithm was employed and identified a total subset of 294
candidate markers that best characterized the five body
fluids in the microarray dataset (see Electronic supplemen-
tary materials, Fig. 1). Further manual ascertainment of the
most promising candidate markers from this list was
performed considering the fold change of differential
expression and absolute expression levels, resulting in
small candidate markers sets for each tissue for validation
by quantitative RT-PCR.
Validation of candidate miRNA markers
A total of 14 most promising candidate markers (two to four for
each of the five body fluids) were selected from the microarray
dataset for validation in TaqMan-based quantitative RT-PCR
assays (Table 1). This step was important not only as technical
confirmation of the microarray results using an independent
methodology but also because RT-PCR assays, instead of
microarray profiling, can easily be applied to forensic
samples. All ascertained candidate miRNAs could be detected
with commercially available TaqMan assays, irrespective of
whether multiplex (pentaplex) or singleplex cDNA synthesis
reactions were performed. Three small RNAs, RNU24,
RNU44, and RNU48 used as endogenous reference
controls, demonstrated similar levels of expression within
each sample and irrespective of the sample origin.
The level of agreement between the microarray and RT-
PCR (TaqMan) expression profiling results was highly
dependent on the body fluid in focus. In particular, the
expression patterns of semen and venous blood-targeting
candidate markers were highly concordant between both
Int J Legal Med (2010) 124:217–226 219detection methodologies. Both the microarray and the RT-
PCR (TaqMan) analyses confirm the over-expression of
candidate miRNAs in the target body fluids and show an
overall high correlation between microarray and RT-PCR
results (Fig. 2). Three miRNAs, miR-20a, miR-106a, and
miR-185, revealed high expression levels in venous blood
relative to all other body fluids tested, including menstrual
blood and with agreeing results from both technologies
(except for a single individual menstrual blood sample
where miR-185 expression was in the range of venous
blood). Furthermore, four miRNAs, miR-135a, miR-10a,
miR-507, and miR-943, appeared strongly over-expressed
in semen relative to all other body fluids tested and with
agreeing results from both technologies. However, less
concordance between microarray and RT-PCR results was
achieved for the other three body fluids (Electronic
supplementary materials, Fig. 2). In particular, TaqMan
analysis of the microarray candidate markers for menstrual
blood revealed that miR-144 was down-regulated in semen,
saliva, and vaginal secretion, in agreement with the micro-
array results. However, miR-144 expression from TaqMan
analysis appeared more abundant in venous blood than in
Fig. 1 Unsupervised hierarchi-
cal clustering of 458 different
miRNAs from microarray anal-
ysis of five forensically relevant
body fluids, i.e., semen (SE),
saliva (SA), vaginal secretion
(VS), menstrual blood (MS), and
whole venous blood (WB) from
several individuals. Note the
clustering of samples according
to body fluids based on the
miRNA expression
Menstrual blood Venous blood Semen Saliva Vaginal secretion
hsa-miR-185* hsa-miR-20a hsa-miR-943 hsa-miR-583 hsa-miR-617
hsa-miR-144 hsa-miR-106a hsa-miR-135a hsa-miR-518c* hsa-miR-891a
hsa-miR-185 hsa-miR-10a hsa-miR-208b
hsa-miR-507
Table 1 Candidate miRNA
markers with differential
expression patterns in five body
fluids as derived from
microarray data analysis and
used for RT-PCR confirmation
analysis
220 Int J Legal Med (2010) 124:217–226menstrual blood in disagreement with the microarray data
(Fig. 2a). Hence, our RT-PCR data suggest that miR-144 is
a useful marker for all kinds of blood samples (including
menstrual blood), but this miRNA was not confirmed as
specific menstrual blood marker. Another microarray
candidate marker for menstrual blood, miR-185*, showed
a non-specific expression across all body fluids in the RT-
PCR results not agreeing with the microarray results
(Electronic supplementary materials, Fig. 2). Also the
miRNAs, miR-583, miR-518c*, and miR-208b identified
by microarray analysis as candidate markers for saliva and
miR-617 for vaginal secretion, demonstrated a strong
discordance between microarray and TaqMan data (Elec-
tronic supplementary materials, Fig. 2). None of these
markers displayed the expected expression pattern when
assayed by RT-PCR. In an attempt to find specific markers
for saliva, vaginal secretion, and menstrual blood, one
additional miRNA candidate marker per each tissue was
ascertained from the microarray data, i.e., miR-9*, miR-
203, and miR-296*, respectively. The usefulness of these
additional markers was examined in a limited number of
individual samples (e.g., one to two per tissue). However,
no over-expression in the targeted body fluids was observed
for any of these additional markers (results not shown).
Recently, a set of nine miRNA markers with differential
expression in the same five body fluids studied here was
reported by Hanson et al. [13]. Except for two semen
markers, miR-135b and miR-10b, which are closely related
to (but not identical with) miR-135a and miR-10a identified
in our screen, there was no overlap with the 14 candidate
miRNAs selected by us. Given our problems in identifying
reliable miRNA markers for vaginal secretion, menstrual
blood, and saliva, we tested the expression of the seven
markers from Hanson et al. that were unrelated to our
candidate markers, by quantitative RT-PCR (TaqMan) in
our sample set (Electronic supplementary materials, Fig. 3).
We were only able to replicate the Hanson et al. results for
markers these authors suggested for venous blood (miR-16
and miR-451) and semen (miR-10b and miR-135b), but not
for those they suggested for saliva (miR-205 and miR-658),
vaginal secretion (miR-124a and miR-372), and menstrual
blood (miR-412). There may be several explanations for the
observed discrepancies between our and the published
findings for the latter three body fluids. First, we used
TaqMan RT-PCR technology from Applied Biosystems,
whereas Hanson et al. utilized SYBR Green assays from
Qiagen, which implies different strategies for both cDNA
synthesis and PCR quantification. Second, the relatively
small sample size, especially in our study, does not allow
ruling out the natural variation of miRNA expression that
may exist between individuals. However, it did not escape
our attention that the two body fluids, i.e., venous blood
and semen, for which we could successfully identify and
validate specific miRNA markers, are the same two body
fluids for which we could replicate the findings of Hanson
et al. Conversely, the three body fluids (saliva, vaginal
secretion, and menstrual blood) for which we were unable
to reliably identify specific miRNA markers in our own
screening experiments could also not be identified on the
basis of the miRNA markers proposed by Hanson et al. (see
below for further explanation).
Notably, the most striking case of disagreement between
our microarray and RT-PCR data was observed for miR-891a.
According to our microarray data, this particular miRNA
appeared to be highly over-expressed in vaginal secretion,
whereas our quantitative RT-PCR (TaqMan) assay demon-
strated that it was highly and exclusively expressed in semen
(Fig.3a). A literature search revealed, according to one of the
large-scale screening studies [14], that this miRNA is present
only in epididymis tissue (i.e., part of testicular system where
sperm cells maturate) and was practically absent from any
other tissue analyzed. This suggested that our microarray
data regarding miR-891a possibly reflect an artifact. To test
this assumption, we analyzed total RNA from both semen
and vaginal secretion by Northern blotting using a biotiny-
lated LNA™ probe targeting miR-891a. The presence of an
RNA species of the expected size of 22 bases in the semen
samples (highlighted by circle in Fig. 3b)u n e q u i v o c a l l y
showed that miR-891a is indeed expressed in semen. No
hybridization signal of a RNA species with expected
fragment size was observed in the vaginal secretion samples
(Fig. 3b). Consequently, we established miR-891a as marker
highly over-expressed in semen. Moreover, as seen on the
Northern blot, the lanes containing the vaginal secretion
samples showed a very strong non-miRNA hybridization
signal in the high molecular weight area (highlighted by
rectangle in Fig. 3b). This may indicate that the vaginal
secretion samples contained RNA species that cross-
hybridize with the miR-891a probe, thereby explaining the
erroneous result for miR-891a expression in the microarray
analysis. The LNA™- modified oligonucleotide miRNA
capture probes are designed not to cross-hybridize with other
human RNA species (Exiqon, Vadbæk, Denmark). There-
fore, one may assume that the cross-hybridizing bands on the
Northern blots in the vaginal secretion samples are not
derived from the human transcriptome, but perhaps from
bacterial and/or fungal RNA, which is expected to be present
in total RNA extracts from vaginal samples. This would
explain why our microarray experiments failed to identify
specific miRNA markers in vaginal secretion. Moreover, the
same explanation may apply to saliva and menstrual blood
and our inability to identify reliable miRNA markers, since
also these body fluids are naturally contaminated with
bacteria and fungi. An alternative explanation for the cross-
hybridizing bands in the case of miR-891a is that in vaginal
samples, mir-891a may not be properly processed to its
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hybridizing bands of 60–75 bases in one of vaginal samples)
or as primary miRNA transcript (cf. the hybridizing bands
>300 bases in both samples). The LNA™ capture probes
used in microarray and Northern blot hybridization may not
be able to discriminate mature and unprocessed miRNA. In
contrast, stem-loop primers used at reverse transcription step
in RT-PCR TaqMan technology are specific only to short
mature miRNA molecules, which also make TaqMan
method less affected by potentially contaminating bacterial/
fungal RNA. Future screening for candidate miRNA markers
for saliva, vaginal secretion, and menstrual blood employing,
e.g., highly specific TaqMan technology from Applied
Biosystems, may reveal promising markers.
Time-wise stability of miRNA markers
The effect of long-term storage on the detection of miRNAs
wastestedbyRT-PCR.Weexaminedthe stabilityoftheblood
markers miR-185, miR-106a, and miR-144 and the semen
markers miR-135a, miR-10a, miR-507, and miR-891a using
quantitative RT-PCR (TaqMan) assays. The same blood and
semensamplesasusedintheinitialexperimentswereagedfor
1 year under lab conditions (relatively constant humidity and
ambient temperature, no UV exposure, dust free, etc.). The
comparison of PCR results from fresh and 1-year old samples
plottedinparallel(Electronic supplementarymaterials,Fig. 4)
revealed strong similarity in expression profiles and absolute
expression levels. It is remarkable that not only miRNAs
could be easily detected in experimentally aged body fluid
samples but also that the absolute levels do not seem to be
diminished in old samples. Thus, in agreement with the
expectation based on the very small size of miRNAs,
practically no effect of time-wise degradation was detected
for the miRNA markers tested. Unfortunately, the amount of
RNA available in this experiment was limited and did not
allow testing the blood marker miR-20a and the semen
marker miR-943. However, based on the results of the seven
markers tested and the general assumption that miRNAs
should not be sensitive to in vitro degradation processes due
to their small size, there is no apparent reason to expect the
degradation behavior of these two miRNAs being signifi-
cantly different. Although the evaluation of the effect of
environmental factors other than time (such as humidity,
temperature, and UVradiation) on miRNA degradation is yet
to be investigated in more detailed validation studies, and the
excellent time-wise stability of the miRNA markers tested
here holds a great promise for forensic applications.
Sensitivity of miRNA TaqMan assays
We used serial dilutions of total RNA (10-fold dilution
from 20 to 0.002 ng) isolated from fresh venous blood and
semen samples as input for cDNA synthesis, 1/18 of which
was used in single PCR test, to establish the detection
sensitivity of TaqMan RT-PCR assays for two blood (miR-
144 and miR-185) and two semen (miR-135a and miR-
891a) miRNA markers. These four markers were chosen for
sensitivity testing because they appeared most abundant
and most differentially expressed according to the TaqMan
analyses. Hence, they serve as best miRNA markers for
blood and semen from our study and the sensitivity levels
of their respective TaqMan assays are of relevance for
future forensic applications. Strikingly, all four markers
were detectable in the target body fluid using the lowest
amount of 2 pg total RNA for cDNA synthesis, thus
corresponding to as little as 0.1 pg RNA per single RT-PCR
test (Electronic supplementary materials, Fig. 5). Such
amount of total RNA corresponds to single cell level and
is much lower than usually needed for successful RT-PCR
detection of mRNAs [9]. Therefore, we expect the miRNA
markers suggested here for blood and semen identification
to be useful for most forensic cases. It will be interesting to
see in future forensic validation studies how the high assay
sensitivities established here from variation of template
RNA concentrations translate to variation in stain size
including different surface materials.
A different aspect of TaqMan assay sensitivity relevant for
forensic applications is species specificity. Although we
consider experimental testing something for future forensic
validation studies, we searched existing information on the
markers studied here by RT-PCR. From the “Assay Index File
v8 for miRNA” material available online from the assay
manufacturer, only information of two mammal species
(mouse and rat) was obtainable for species specificity of the
assays used. In addition, we explored the Sanger miRNA
database to search for complete homology of the human
miRNA markersequences with any other speciesandselected
results of the most relevant species, chimpanzee, dog, and
chicken. As evident from this (limited) combined information
(Electronic supplementary materials, Table 1), some miRNA
markers appear specific to the human species, whereas others
do not. This is not unexpected as in general miRNAs are
known to be extremely conservative across species; however,
some human miRNA are differed by one or few bases from
the closest orthologs, which can be reflected in human-
specific TaqMan assays. Of the four blood markers high-
Fig. 2 TaqMan RT-PCR expression profiles of candidate miRNAs
markers over-expressed in whole venous blood (a) or semen (b)
according to microarray analysis. The plots on the left side show RT-
PCR data from five body fluids (for abbreviations, see the legend to
Fig. 1) and several individuals as mean fold-change values of
technical replicate reactions ±SD. The plots on the right side show
correlation between microarray expression signals and RT-PCR data
for the same miRNA marker
b
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224 Int J Legal Med (2010) 124:217–226lighted here, only one appears human specific considering
the available species data (miR-106a, which is not the most
stringent blood marker we identified). Of the five semen
markers highlighted, one is human specific (miR-891a,
which is one of our most stringent semen markers), and
two appear specific to human and non-human primates
(miR-943 and miR-507). However, even if a miRNA marker
itself is not human specific, the final conclusions retrievable
from the approach we propose here for forensic application
will still reveal human-specific information because the
TaqMan assays of the three reference genes we used for
normalization purposes are human specific.
Conclusions
Screening a large set of 718 human miRNA markers in all
forensically relevant body fluids using the most compre-
hensive microarray platform currently available, we identi-
fied several RT-PCR confirmed miRNA markers that
appeared over-expressed either in venous blood or in
semen. We found that these blood and semen miRNA
markers were practically not prone to degradation in samples
stored for 1 year. Our results highlight four miRNA markers
for blood identification (miR-20a, miR-106a, miR-185, and
miR-144) and five for semen identification (miR-135a, miR-
10a, miR-507, miR-943, and miR-891a). Of those, two
miRNA markers for blood (miR-144 and miR-185) and two
others for semen (miR-135a and miR-891a) are suggestive to
be most useful for body fluid identification in future forensic
applications, and the respective RT-PCR assays used here for
their detection were highly sensitive, allowing the reliable
marker detection from subpicogram amounts of total RNA.
Our results proved the applicability of the miRNA approach
for forensic body fluids identification. However, despite that
microarray analysis revealed distinct sets of differentially
expressed miRNAs also for saliva, menstrual blood, and
vaginal secretion, the microarray candidate markers for these
three body fluids could not be confirmed by TaqMan-based
RT-PCR. Hence, additional work remains to be carried out in
search for miRNA markers for saliva, menstrual blood, and
vaginal secretion identification and employing more suitable
technology platform than applied here. Future work may
also reveal the cell type of miRNA expression of the miRNA
markers highlighted here, which may be relevant for certain
forensic application, e.g., in case of semen markers, as well
as additional marker details from dedicated forensic valida-
tion testing.
Acknowledgments We thank all volunteers for providing body fluid
samples. We are grateful to Wilfred van IJcken (Center for Biomics,
Erasmus University Medical Center Rotterdam) for the help in
developing the miRNA microarray platform. This work was supported
in part by funds from the Netherlands Forensic Institute, Fonds
Schiedam-Vlaardingen, and received additional support by a grant
from the Netherlands Genomics Initiative (NGI)/Netherlands Organi-
zation for Scientific Research (NWO) within the framework of the
Forensic Genomics Consortium Netherlands (FGCN).
Fig. 3 Expression profile of
miRNA marker miR-891a. a
Expression of miR-891a
according to microarray and
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hybridized with a miR-891a
specific LNA™ oligonucleotide
(L size ladder)
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